Brief: Urogen Announces FDA Advisory Committee For Ugn-102, An Investigational Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
07/05/2025 14:29
Urogen Pharma Ltd UR8.F: UROGEN ANNOUNCES FDA ADVISORY COMMITTEE FOR UGN-102, AN INVESTIGATIONAL TREATMENT FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER UROGEN PHARMA LTD - FDA SCHEDULES ODAC MEETING FOR UROGEN'S UGN-102 ON MAY 21, 2025 UROGEN PHARMA LTD - FDA TARGETS JUNE 13, 2025 FOR UGN-102 REVIEW COMPLETION Source text: ID:nBw7pbL6Ta Further company coverage: UR8.F
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors